EP4716697A2 - Antikörper und verwendungen davon - Google Patents

Antikörper und verwendungen davon

Info

Publication number
EP4716697A2
EP4716697A2 EP24729242.8A EP24729242A EP4716697A2 EP 4716697 A2 EP4716697 A2 EP 4716697A2 EP 24729242 A EP24729242 A EP 24729242A EP 4716697 A2 EP4716697 A2 EP 4716697A2
Authority
EP
European Patent Office
Prior art keywords
seq
sequence identity
nos
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24729242.8A
Other languages
English (en)
French (fr)
Inventor
Niklas LANDBERG
Thoas Fioretos
Carl SANDÉN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lead Biologics International AB
Original Assignee
Lead Biologics International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Biologics International AB filed Critical Lead Biologics International AB
Publication of EP4716697A2 publication Critical patent/EP4716697A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP24729242.8A 2023-05-23 2024-05-23 Antikörper und verwendungen davon Pending EP4716697A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE2350624 2023-05-23
PCT/EP2024/064282 WO2024240896A2 (en) 2023-05-23 2024-05-23 Antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EP4716697A2 true EP4716697A2 (de) 2026-04-01

Family

ID=91302412

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24729242.8A Pending EP4716697A2 (de) 2023-05-23 2024-05-23 Antikörper und verwendungen davon

Country Status (6)

Country Link
EP (1) EP4716697A2 (de)
JP (1) JP2026518257A (de)
KR (1) KR20260016915A (de)
CN (1) CN121175337A (de)
AU (1) AU2024278032A1 (de)
WO (1) WO2024240896A2 (de)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
TW200823237A (en) * 2006-08-28 2008-06-01 Nuvelo Inc Antibodies to NTB-A
KR20180021705A (ko) 2015-06-30 2018-03-05 시애틀 지네틱스, 인크. 항-ntb-a 항체 및 관련 조성물 및 방법
JP7604401B2 (ja) * 2019-07-03 2024-12-23 オックスフォード バイオセラピューティックス リミテッド 抗体および使用方法
WO2021111005A1 (en) 2019-12-06 2021-06-10 Thoas Fioretos Novel agents and uses thereof

Also Published As

Publication number Publication date
WO2024240896A3 (en) 2025-02-06
WO2024240896A2 (en) 2024-11-28
KR20260016915A (ko) 2026-02-04
JP2026518257A (ja) 2026-06-04
CN121175337A (zh) 2025-12-19
AU2024278032A1 (en) 2025-11-20

Similar Documents

Publication Publication Date Title
JP2023109927A (ja) ヒトのがんを治療するための特異的抗ｃｄ３８抗体
DK2665749T3 (en) Anti-il1rap antibodies and their use for the treatment of solid tumors
KR102959291B1 (ko) Ceacam5 및 cd47에 대한 이중특이성 항체
KR101968498B1 (ko) 암의 치료 및/또는 예방용 의약 조성물
EP4512418A2 (de) Dosierstrategie zur abschwächung des zytokinfreisetzungssyndroms für bispezifische cd3/cd20-antikörper
CN113929782B (zh) 对淋巴细胞中抑制途径的中和
CN113286634A (zh) 对gucy2c特异性的抗体及其用途
KR20180089444A (ko) 암을 치료하기 위한 항-pd-1 항체와 이특이적 항-cd20/항-cd3 항체의 조합
WO2018133842A1 (zh) 人程序性死亡受体pd-1的单克隆抗体及其片段
KR20210089179A (ko) Cll1을 표적으로 하는 항체 및 이의 응용
JP6649941B2 (ja) Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
KR20190035863A (ko) 암 치료를 위한 항Siglec-7 항체
EP2725037A1 (de) Monoklonale Antikörper gegen Canidae CD20
JP6914283B2 (ja) ヒトのがんを治療するための特異的抗ｃｄ３８抗体
WO2020232165A1 (en) Bispecific anti-cd3 x cd20 antibodies and uses thereof
CN115279406A (zh) 蛋白质治疗剂的调配物
CA3224693A1 (en) Anti-tnfr2 antibody and uses thereof
JP2022526640A (ja) 血液悪性腫瘍の治療における二重特異性ｃｄ１２３×ｃｄ３ダイアボディの投薬レジメン
CN109069629B (zh) 癌的治疗和/或预防用药物组合物
WO2021207681A1 (en) Targeted reduction of activated immune cells
JP2023506593A (ja) 抗ｇｉｔｒ抗体およびその使用
AU2024278032A1 (en) Antibodies and uses thereof
WO2024146553A1 (en) Antibodies against cd47, method for preparing the same, and use thereof
WO2025245150A1 (en) Anti-pd-1 x il-25 bispecific antibody to treat cancer
HK40110316A (en) Neutralization of inhibitory pathways in lymphocytes

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251201

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR